CAR-Ms developed from genetically modified human peritoneal macrophages specifically targeted HER2-expressing GC cells, triggered phagocytosis, significantly promoted tumor regression in HER2-positive models, extended overall survival (OS) in mouse models of peritoneal carcinomatosis, and offer a promising treatment option for HER2-positive GC patients [176]. This evidence concerns the gene ERBB2 and gastric cancer.